Supplementary Figure 1 from Measurement of Tumor VEGF-A Levels with &lt;sup&gt;89&lt;/sup&gt;Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model